GUD

Knight Therapeutics Inc. announces voting results from the Annual General Meeting

Retrieved on: 
Wednesday, May 10, 2023
GUD, Annual, Knight, TSX, Shareholder, Corporation, Meeting, Proxy, Video game, Holding company

MONTREAL, May 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual General Meeting of the Shareholders held virtually in Montreal, Quebec ("Meeting").

Key Points: 
  • MONTREAL, May 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual General Meeting of the Shareholders held virtually in Montreal, Quebec ("Meeting").
  • Each director nominee listed in the Management Information Circular dated April 6, 2023 ("Circular") was elected as Director of the Corporation at the Meeting.
  • Shareholders present in person or represented by proxy at the Meeting voted as follows:

Knight to Present at the 2023 RBC Capital Markets Global Healthcare Conference in New York City

Retrieved on: 
Tuesday, May 9, 2023
GUD, TSX, InterContinental New York Barclay Hotel, Conference, Private investigator

MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 10:30 am ET at the InterContinental New York Barclay hotel in New York City.

Key Points: 
  • MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 10:30 am ET at the InterContinental New York Barclay hotel in New York City.

Notice of Knight Therapeutics' First Quarter 2023 Results Conference Call

Retrieved on: 
Thursday, May 4, 2023
GUD, Knight, TSX, Video game, Private investigator

MONTREAL, May 04, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2023 financial results on Thursday, May 11, 2023 prior to market opening.

Key Points: 
  • MONTREAL, May 04, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2023 financial results on Thursday, May 11, 2023 prior to market opening.
  • Following the release, Knight will hold a conference call and audio webcast.
  • Knight cordially invites all interested parties to participate in this call.

Knight to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Tuesday, April 18, 2023
GUD, Metro Toronto Convention Centre, TSX, Conference, Pharmaceutical industry

MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:  GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 25, 2023 at 1:30 p.m.

Key Points: 
  • MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:  GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 25, 2023 at 1:30 p.m.
  • ET at the Metro Toronto Convention Centre in Toronto.
  • A copy of the presentation will be available at www.gud-knight.com .

Knight Therapeutics Inc. ranks on The Globe and Mail’s fourth-annual Women Lead Here benchmark of executive gender diversity

Retrieved on: 
Friday, March 24, 2023
GUD, TSX, Parity, Business, Woman, Management, Knight, Report

MONTREAL, March 24, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been included on The Globe and Mail’s 2023 Report on Business magazine’s Women Lead Here list.

Key Points: 
  • MONTREAL, March 24, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been included on The Globe and Mail’s 2023 Report on Business magazine’s Women Lead Here list.
  • This annual editorial benchmark identifies top-notch Canadian businesses with the highest executive gender diversity.
  • This benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to determine Canadian corporations with the highest degree of gender diversity among executive ranks.
  • “We are proud and humbled to see Knight Therapeutics Inc. included on the Globe and Mail’s Report on Canada’s Women Lead Here as one of the leading companies in executive gender diversity in corporate Canada and specialty pharmaceutical sector,” said Samira Sakhia, President and Chief Executive Officer of Knight.

Notice of Knight Therapeutics' Fourth Quarter and Year End 2022 Results Conference Call

Retrieved on: 
Thursday, March 16, 2023
GUD, TSX, Knight, Video game, Private investigator

MONTREAL, March 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2022 financial results on Thursday, March 23, 2023 prior to market opening.

Key Points: 
  • MONTREAL, March 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2022 financial results on Thursday, March 23, 2023 prior to market opening.
  • Following the release, Knight will hold a conference call and audio webcast.
  • Knight cordially invites all interested parties to participate in this call.

Knight Therapeutics Closes US$38.5 million Loan with IFC

Retrieved on: 
Friday, December 23, 2022
GUD, TSX, Partnership, International Finance Corporation, Therapy, Private sector, World Bank Group, Security (finance), Brazilian real, Knight

MONTREAL, Dec. 23, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has closed a five-year, US$38.5 million secured loan denominated in select Latin American currencies with the International Finance Corporation (“IFC”), a member of the World Bank Group focused on the private sector in emerging markets.

Key Points: 
  • MONTREAL, Dec. 23, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has closed a five-year, US$38.5 million secured loan denominated in select Latin American currencies with the International Finance Corporation (“IFC”), a member of the World Bank Group focused on the private sector in emerging markets.
  • The IFC loan is denominated in Brazilian Real, Colombian Peso, Chilean Peso and Mexican Peso, with the Brazilian Real tranche representing approximately 50% of the loan and the balance split among the rest of the currencies.
  • The IFC loan maturity date is on October 15, 2027, with principal repayments starting on October 15, 2023.
  • Furthermore, the loan has customary covenants and is secured by select assets of Knight including a cash collateral of 35% of the principal outstanding.

Knight Announces Relaunch of AKYNZEO® in Canada

Retrieved on: 
Thursday, December 1, 2022
Dexamethasone, Palonosetron, Nature, TSX, Nausea, Museo-laboratorio della Civiltà Contadina (Museum-workshop of the Peasant Culture), Therapy, Patient, Annual report, Oncology, Vomiting, Breast cancer, Cancer, GUD, Pharmaceutical industry, Uniting Medically Supervised Injecting Centre, Knight, IQVIA

MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has assumed full commercial activities and is relaunching oral AKYNZEO (netupitant/palonosetron capsules) in Canada.

Key Points: 
  • MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has assumed full commercial activities and is relaunching oral AKYNZEO (netupitant/palonosetron capsules) in Canada.
  • Knight and Helsinn Healthcare SA ("Helsinn") entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI oral/IV (palonosetron) in Canada (the "Products") in May 2022.
  • According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7 million in 2021.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Knight to Present at Stifel Healthcare Conference

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Nature, Laboratorio museotecnico Goppion, Intention, Therapy, Annual report, Conference, TSX, Lotte New York Palace Hotel, GUD, Uniting Medically Supervised Injecting Centre

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Key Points: 
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries.

Notice of Knight Therapeutics' Third Quarter 2022 Results Conference Call

Retrieved on: 
Thursday, November 3, 2022
Nature, TSX, Annual report, Intention, Laboratorio de Energía Solar Termoeléctrica, GUD, Therapy, Uniting Medically Supervised Injecting Centre

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Key Points: 
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .
  • Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.